fingolimod hydrochloride has been researched along with Graves Ophthalmopathy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banga, JP; Bechrakis, NE; Berchner-Pfannschmidt, U; Diaz-Cano, S; Eckstein, A; Hansen, W; Hendgen-Cotta, UB; Hose, M; Michel, L; Plöhn, S; Schlüter, A | 1 |
| Chae, MK; Kim, SE; Lee, EJ; Lee, JH; Yoon, JS | 1 |
2 other study(ies) available for fingolimod hydrochloride and Graves Ophthalmopathy
| Article | Year |
|---|---|
Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Topics: Animals; Autoantibodies; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Graves Disease; Graves Ophthalmopathy; Mice; Mice, Inbred BALB C; Receptors, Thyrotropin; T-Lymphocytes, Regulatory | 2019 |
The Role of Sphingosine-1-Phosphate in Adipogenesis of Graves' Orbitopathy.
Topics: Adipogenesis; Adult; Blotting, Western; CCAAT-Enhancer-Binding Protein-beta; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cells, Cultured; Female; Fibroblasts; Fingolimod Hydrochloride; Graves Ophthalmopathy; Humans; Immunosuppressive Agents; Lysophospholipids; Male; Middle Aged; Orbit; PPAR gamma; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine | 2016 |